Medicare approved the groundbreaking new cell-based gene therapy drug, Encelto, for use in the ambulatory surgical center setting, effective for claims with dates of service on or after October 1,…
Beginning in 2008, CMS adjusts ASC rates for geographic differences in wages using the geographic locality definitions initially established in 2003 by the Office of Management and Budget (OMB).
Pass-through status is determined for newly FDA-approved drug and device products on an individual basis. Review this article for more details on pass-through devices in an ambulatory surgical center…